Ecoclimber
Senior Member
- Messages
- 1,011
Rituximab review
Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013 Jul 2;8(7):e66308
BACKGROUND:
Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS.
OBJECTIVES:
To evaluate the efficacy and safety of rituximab for MS treatment.
DATA COLLECTION:
Studies were selected if they were clinical trials, irrespective of the dosage or combination therapies.
MAIN RESULTS:
Four studies with a total of 599 patients were included. One assessed the efficacy of rituximab for primary progressive (PP) MS while the other three focused on relapsing-remitting (RR) MS.
In the PPMS study, rituximab delayed time to confirmed disease progression (CDP) in pre-planned sub-group analyses. The increase in T2 lesion volume was lower in the rituximab group at week 96 compared with placebo.
For the RRMS studies, an open-label phase I study found that rituximab reduced the annualized relapse rate to 0.25 from pre-therapy baseline to week 24, while in the randomized placebo-controlled phase II trial, annualized relapse rates were 0.37 in the rituximab group and 0.84 in the placebo group (p = 0.04) at week 24.
Rituximab dramatically reduced the number of gadolinium-enhancing lesions on brain MRI scans for both RRMS studies.
Off-label rituximab as an add-on therapy in patients with breakthrough disease on first-line agents was associated with an 88% reduction when comparing the mean number of gadolinium-enhancing lesions prior to and after the treatment.
Although frequent adverse events classified as mild or moderate occurred in up to 77% of the patients, there were no grade 4 infusion-related adverse events. AUTHOR’S
CONCLUSION:
Despite the frequent mild/moderate adverse events related to the drug, rituximab appears overall safe for up to 2 years of therapy and has a substantial impact on the inflammatory disease activity (clinical and/or radiological) of RRMS. The effect of rituximab on disease progression in PPMS appears to be marginal.
Anti-CD20 antibodies inhibit relapsing disease but does not appear to inhibit non-relapsing progressive MS
For Comments from the Mouse Doctors Click Below:
http://multiple-sclerosis-research.blogspot.co.uk/2013/07/rituximab-review.html
Since this deals with an autoimmune disease, it is interesting comments for MS
Eco
BACKGROUND:
Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS.
OBJECTIVES:
To evaluate the efficacy and safety of rituximab for MS treatment.
DATA COLLECTION:
Studies were selected if they were clinical trials, irrespective of the dosage or combination therapies.
MAIN RESULTS:
Four studies with a total of 599 patients were included. One assessed the efficacy of rituximab for primary progressive (PP) MS while the other three focused on relapsing-remitting (RR) MS.
In the PPMS study, rituximab delayed time to confirmed disease progression (CDP) in pre-planned sub-group analyses. The increase in T2 lesion volume was lower in the rituximab group at week 96 compared with placebo.
For the RRMS studies, an open-label phase I study found that rituximab reduced the annualized relapse rate to 0.25 from pre-therapy baseline to week 24, while in the randomized placebo-controlled phase II trial, annualized relapse rates were 0.37 in the rituximab group and 0.84 in the placebo group (p = 0.04) at week 24.
Rituximab dramatically reduced the number of gadolinium-enhancing lesions on brain MRI scans for both RRMS studies.
Off-label rituximab as an add-on therapy in patients with breakthrough disease on first-line agents was associated with an 88% reduction when comparing the mean number of gadolinium-enhancing lesions prior to and after the treatment.
Although frequent adverse events classified as mild or moderate occurred in up to 77% of the patients, there were no grade 4 infusion-related adverse events. AUTHOR’S
CONCLUSION:
Despite the frequent mild/moderate adverse events related to the drug, rituximab appears overall safe for up to 2 years of therapy and has a substantial impact on the inflammatory disease activity (clinical and/or radiological) of RRMS. The effect of rituximab on disease progression in PPMS appears to be marginal.
Anti-CD20 antibodies inhibit relapsing disease but does not appear to inhibit non-relapsing progressive MS
For Comments from the Mouse Doctors Click Below:
http://multiple-sclerosis-research.blogspot.co.uk/2013/07/rituximab-review.html
Since this deals with an autoimmune disease, it is interesting comments for MS
Eco